Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives $11.50 Average Price Target from Analysts

Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) have received a consensus rating of “Buy” from the ten research firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $11.50.

Several equities research analysts have recently weighed in on the company. Piper Sandler reduced their price objective on Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Bank of America cut their target price on Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating on the stock in a research report on Friday, August 14th. BTIG Research reaffirmed a “buy” rating on shares of Perspective Therapeutics in a report on Friday, July 24th. Finally, BMO Capital Markets set a $11.00 price target on Perspective Therapeutics and gave the company an “outperform” rating in a research report on Tuesday, August 18th.

Perspective Therapeutics Stock Up 3.9%

Shares of CATX opened at $2.92 on Friday. The firm’s 50 day moving average is $3.08 and its 200-day moving average is $3.71. Perspective Therapeutics has a 12-month low of $1.96 and a 12-month high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last released its earnings results on Monday, August 10th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.03. The business had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.09 million. Perspective Therapeutics had a negative net margin of 28,467.97% and a negative return on equity of 41.92%. On average, research analysts anticipate that Perspective Therapeutics will post -0.98 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Commodore Capital LP acquired a new position in Perspective Therapeutics during the first quarter valued at $26,424,000. Affinity Asset Advisors LLC boosted its position in Perspective Therapeutics by 954.9% during the 1st quarter. Affinity Asset Advisors LLC now owns 3,164,582 shares of the company’s stock worth $13,196,000 after acquiring an additional 2,864,582 shares during the period. Avidity Partners Management LP boosted its position in Perspective Therapeutics by 88.4% during the 1st quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock worth $25,228,000 after acquiring an additional 2,839,266 shares during the period. Spruce Street Capital LP acquired a new stake in Perspective Therapeutics during the 1st quarter worth about $10,955,000. Finally, Yu Fan purchased a new position in Perspective Therapeutics during the 1st quarter valued at about $4,401,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc is a clinical-stage biotechnology company developing precision-targeted radiopharmaceuticals for the treatment of cancer. The company focuses on therapies that combine tumor-targeting molecules with radioactive isotopes designed to deliver radiation directly to malignant cells while limiting exposure to surrounding healthy tissue.

Perspective Therapeutics’ proprietary VMT platform is intended to support the development of both therapeutic and diagnostic radiopharmaceuticals.